Skip to main content

Abiraterone Acetate in Treating Patients with Hormone-Resistant Prostate Cancer

Trial Status: Administratively Complete

This randomized pilot clinical trial studies the best way to give abiraterone acetate in treating patients with hormone-resistant prostate cancer. Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as abiraterone acetate, may lessen the amount of androgen made by the body.

Inclusion Criteria

  • Histologically or cytologically confirmed prostate cancer with progressive disease defined as either: * 2 or more new lesions on bone scan or * Progressive disease on computed tomography (CT)/magnetic resonance imaging (MRI) according to Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 criteria or * Rising PSA: PSA evidence for progressive prostate cancer consists of a minimum PSA level of at least 2 ng/ml, which has subsequently risen on at least 2 successive occasions, at least 2 weeks apart
  • Evidence of castration resistance defined as disease progression despite a testosterone level < 50 ng/dL (or surgical castration)
  • Any prior therapy for castrate disease is acceptable except prior abiraterone, which is excluded; a minimum washout of 28 days for any other anticancer therapy prior to first dose of study drug is required * Any other radiotherapy or radionuclide require 28-day washout prior to first dose of study drug * Denosumab or zoledronic acid are allowed
  • Eastern Cooperative Oncology Group (ECOG) performance status =< 2
  • Total bilirubin =< 1.5 x the upper limit of normal
  • Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvate transaminase [SGPT]) =< 2.5 X institutional upper limit of normal
  • Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria

  • Therapy with other hormonal therapy, including any dose of megestrol acetate (Megace), finasteride (Proscar), dutasteride (Avodart), or any herbal product known to decrease PSA levels (e.g., saw palmetto and PC-SPES), or any systemic corticosteroid (other than prednisone =< 10 mg/day) within 4 weeks prior to first dose of study drug
  • Therapy with supplements or complementary is excluded with the following exceptions; all other supplements must be discontinued prior to initiation of study drug * Conventional multivitamin supplements * Selenium * Lycopene * Soy supplements
  • Inability to swallow capsules or known gastrointestinal malabsorption
  • History of other malignancies, with the exception of adequately treated non-melanoma skin cancer or adequately treated superficial bladder cancer or other solid tumors curatively treated with no evidence of disease for >= 5 years from enrollment
  • Blood pressure that is not controlled despite > 2 oral agents (systolic blood pressure [SBP] > 160 and diastolic blood pressure [DBP] > 90 documented during the screening period with no subsequent blood pressure readings < 160/100)
  • Serum potassium (K)+ < 3.5 mmoL/L; patients with a K+ < 3.5 mmoL/L are required to have a documented subsequent K+ > 3.5 prior to enrollment to be eligible
  • Serious intercurrent infections or non-malignant medical illnesses that are uncontrolled
  • Active psychiatric illness/social situations that would limit compliance with protocol requirements
  • New York Heart Association (NYHA) class II, NYHA class III, or IV congestive heart failure (any symptomatic heart failure)
  • Concurrent therapy with strong inhibitors or inducers of cytochrome P450 family 3, subfamily A, polypeptide 4 (CYP3A4) due to concerning possible drug-drug interactions with abiraterone


Emory University Hospital / Winship Cancer Institute
Contact: Bradley Curtis Carthon
Phone: 404-778-1868


Northwestern University
Contact: Timothy M. Kuzel
Phone: 312-695-6180
University of Chicago Comprehensive Cancer Center
Contact: Russell Zelig Szmulewitz
Phone: 773-702-7609
NorthShore University HealthSystem-Evanston Hospital
Contact: Bruce E. Brockstein
Phone: 847-570-1381
Ingalls Memorial Hospital
Contact: Mark Farrell Kozloff
Phone: 708-915-6747
Illinois CancerCare-Peoria
Contact: Sachdev P. Thomas
Phone: 309-243-3000
Southern Illinois University School of Medicine
Contact: John E. Godwin
Phone: 503-215-6412


Fort Wayne
Fort Wayne Medical Oncology and Hematology Inc-Parkview
Contact: Sreenivasa R. Nattam
Phone: 260-484-8830


National Cancer Institute
Contact: William Douglas Figg
Phone: 301-402-3623


Ann Arbor
University of Michigan Comprehensive Cancer Center
Contact: Maha H. A. Hussain
Phone: 800-865-1125


I. To compare the pharmacodynamic effect of reduced dose (250 mg daily) abiraterone acetate in the prandial state (250 mg-Fed) to the full, standard 1000 mg daily dose in the fasting state (1000 mg-Fasting) as assessed by change in serum prostate-specific antigen (PSA).


I. To evaluate the effect of prandial states on plasma levels and the intra-patient pharmacokinetic variability of abiraterone acetate.

II. To evaluate the safety profile of reduced dose abiraterone acetate taken in the prandial state.

III. To evaluate the pharmacodynamic effect of reduced dose abiraterone acetate in the prandial state as assessed by reduction in the extra-gonadal androgen dehydroepiandrosterone sulfate (DHEA-S) and dehydroepiandrostenedione (DHEA).

IV. To evaluate the effect of prandial state on time to disease progression (Working group criteria).

V. To assess and describe medication adherence to abiraterone acetate for both dosing schedules.

OUTLINE: Patients are randomized to one of two treatment arms.

ARM I: Patients receive abiraterone acetate orally (PO) daily first thing in morning after an overnight fast of at least 8 hours and prednisone PO twice daily (BID).

ARM II: Patients receive abiraterone acetate PO daily within 30 minutes of a conventional low-fat breakfast and prednisone as in Arm I.

In both arms, courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up within 30 days.

Trial Phase Phase II

Trial Type Treatment

Lead Organization
University of Chicago Comprehensive Cancer Center

Principal Investigator
Russell Zelig Szmulewitz

  • Primary ID 11-0709
  • Secondary IDs NCI-2012-00116
  • ID NCT01543776